Immuno-oncology

all catalysts(0)

nothing on the calendar yet

News(10)

• 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
  Following their blowout win in melanoma last month, Merck and Moderna are leading the way among a new crop of personalized cancer vaccines. Here are five companies with similar therapies hoping to…
  biospace · 20d ago
• After a brief storm of political headwinds, mRNA is back with strong momentum
  A year to the day after the Trump administration slashed $500 million in funding from mRNA-based programs, the FDA approved Moderna’s flu vaccine based on the technology. Weeks later, Moderna and M…
  biospace · 20d ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 22d ago
• Solstice rises with $225M to develop next-gen CTLA-4 drug from China
  Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from…
  biospace · 24d ago
• A new immuno-oncology play raises $225M for a next-generation drug
  Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.
  biopharma_dive · 24d ago
• Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
  Inhibrx Biosciences’ CEO has argued that the 9.6 months of progression-free survival demonstrated by its OX40 agonist in a phase 2 study has proven the therapy’s durability in treating head and nec…
  fiercebiotech · 26d ago
• Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
  New Phase 3 data show that Summit Therapeutics and Akeso’s PD-1/VEGF therapy improved overall survival in patients with a type of lung cancer as compared to Merck’s Keytruda but the results will ne…
  biospace · 1mo ago
• BMS’ neuro renaissance was built on back of Celgene mega-merger
  Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychi…
  biospace · 1mo ago
• Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio
  BioXcel Therapeutics has filed for bankruptcy and lined up a deal for Teva Pharmaceutical to acquire its assets for $57.5 million upfront.
  fiercebiotech · 1mo ago
• Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
  The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival benefit, according to Summit Therapeutics and China-based partner Akeso.
  biospace · 1mo ago